Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of edaravone in preparation of drug for preventing and treating cerebral amyloid angiopathy (CAA)

A technology for edaravone and drug preparation, which is applied in the pharmaceutical field to achieve the effects of preventing continued deposition, inhibiting Aβ aggregation, and eliminating Aβ

Active Publication Date: 2016-06-01
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no effective drugs for the treatment of CAA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of edaravone in preparation of drug for preventing and treating cerebral amyloid angiopathy (CAA)
  • Use of edaravone in preparation of drug for preventing and treating cerebral amyloid angiopathy (CAA)
  • Use of edaravone in preparation of drug for preventing and treating cerebral amyloid angiopathy (CAA)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] In order to further understand the present invention, preferred solutions of the present invention will be described below in conjunction with examples. These descriptions are only to illustrate the features and advantages of the technical solutions of the present invention, but not to limit the protection scope of the present invention.

[0043] 1. Thioflavin T fluorescence test

[0044] Inhibitory effect of Edaravone on Aβ aggregation: 10 μM Aβ42 and different concentrations of Edaravone solutions (0 μM, 1.56 μM, 3.13 μM, 6.25 μM, 11.25 μM, 25.0 μM, 50.0 μM and 100 μM) in a 37°C incubator Incubate for two days, add 5 μM Thioflavin T working solution and continue to incubate for 20 minutes, and read the OD value with a microplate reader (excitation wavelength is 450 nm, emission wavelength is 482 nm).

[0045] Depolymerization of Edaravone on Aβ fibers: Aβ42 was dissolved in DMEM medium and incubated at 37°C for two days to form Aβ fibers. The formed Aβ fibers were i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy and relates to a use of edaravone in preparation of a drug for preventing and treating cerebral amyloid angiopathy (CAA). The edaravone can remove the amyloid protein (A beta) deposited in brain and prevent A beta deposition in brain.

Description

technical field [0001] The invention belongs to the field of pharmacy. Specifically, the present invention relates to the use of Edaravone for the prevention and removal of Aβ deposition in the brain, especially for the prevention and treatment of cerebral amyloid angiopathy (CAA). Background technique [0002] Cerebral amyloid angiopathy (CAA) refers to the deposition of β-amyloid (Amyloid-betapeptide, Aβ) on the media and adventitia of small and medium-sized arteries (veins with less accumulation) in the cerebral cortex and medulla. Deposition of amyloid in the brain can be a component of any disease. CAA is a morphological hallmark of Alzheimer's disease (AD), but is also frequently seen in elderly patients with normal neurological function. CAA is usually asymptomatic, but can also present as intracranial hemorrhage (ICH), dementia, or transient neurologic abnormalities, with ICH being the most common. Currently there is no effective drug for the treatment of CAA. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4152A61P25/28
CPCA61K31/4152A61K39/395A61K45/06A61K9/08A61K9/20A61K9/48A61P25/28A61K39/3955C07K16/18
Inventor 王延江矫树生姚秀卿周新富
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com